Template:Second-generation BTKi table: Difference between revisions

From Embryology
mNo edit summary
mNo edit summary
Line 6: Line 6:
! width=80px|Selectivity for BTK
! width=80px|Selectivity for BTK
! width=320px|Relevant non-BTK targets
! width=320px|Relevant non-BTK targets
! width=90px|Phase of clinical development
! width=90px|Clinical Phase
|-
|-
| Acalabrutinib  
| Acalabrutinib  

Revision as of 14:10, 30 April 2019

Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors for CCL Treatment
BTK inhibitor BTK binding mechanism Selectivity for BTK Relevant non-BTK targets Clinical Phase
Acalabrutinib Covalent, irreversible High N/A II/III
Zanubrutinib Covalent, irreversible Moderate N/A II/III
Tirabrutinib Covalent, irreversible High N/A I/II
Vecabrutinib Non-covalent, reversible Moderate interleukin-2-inducible (ITK) I/II
LOXO-305 Non-covalent, reversible High N/A I
ARQ-531 Non-covalent, reversible Low Lck/Yes novel tyrosine kinase (LYN),
mitogen-activated protein kinase kinase 1 (MEK1)
I
Table data [1]
  1. Bond DA & Woyach JA. (2019). Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep , , . PMID: 31028669 DOI.